Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRT106 in Combination With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma
NCT07589244Phase 3Recruiting
- Sponsor
- Guangzhou Virotech Pharmaceutical
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 3 trial of VRT-106 in hepatocellular carcinoma (HCC), sponsored by Guangzhou Virotech Pharmaceutical. Started May 2026; status: recruiting.
02
Drugs
VRT-106
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07589244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589244.